clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Insulin Resistance D007333 99 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Stomach Ulcer D013276 75 associated lipids
Hyperlipidemias D006949 73 associated lipids
Colitis D003092 69 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Parkinson Disease D010300 53 associated lipids
Psoriasis D011565 47 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arthritis D001168 41 associated lipids
Lung Diseases D008171 37 associated lipids
Heart Failure D006333 36 associated lipids
Fever D005334 35 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Diarrhea D003967 32 associated lipids
Drug Eruptions D003875 30 associated lipids
Proteinuria D011507 30 associated lipids
Endometriosis D004715 29 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Gastritis D005756 27 associated lipids
Nasal Polyps D009298 26 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Stomach Neoplasms D013274 24 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Fibrosis D005355 23 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Periodontitis D010518 22 associated lipids
Bacterial Infections D001424 21 associated lipids
Myocardial Infarction D009203 21 associated lipids
Helicobacter Infections D016481 21 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Tuberculosis D014376 20 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Peptic Ulcer D010437 19 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Pilotto A et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. 2000 Aliment. Pharmacol. Ther. pmid:10930903
Wong WM et al. Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. 2003 Aliment. Pharmacol. Ther. pmid:12622764
Fischbach L and Evans EL Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. 2007 Aliment. Pharmacol. Ther. pmid:17635369
Spinzi G et al. Randomized study comparing omeprazole plus amoxycillin versus omeprazole plus clarithromycin for eradication of Helicobacter pylori. 1997 Aliment. Pharmacol. Ther. pmid:9146769
Peterson WL The role of antisecretory drugs in the treatment of Helicobacter pylori infection. 1997 Aliment. Pharmacol. Ther. pmid:9146787
Sierra F et al. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. 2013 Aliment. Pharmacol. Ther. pmid:23656465
Kondo Y et al. Helicobacter pylori eradication decreases blood neutrophil and monocyte counts. 2004 Aliment. Pharmacol. Ther. pmid:15298609
Chiba N et al. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. 2004 Aliment. Pharmacol. Ther. pmid:14984382
Di Mario F et al. Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study. 2006 Aliment. Pharmacol. Ther. pmid:16611285
Madisch A et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial. 2006 Aliment. Pharmacol. Ther. pmid:16441467
Fakheri H et al. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. 2001 Aliment. Pharmacol. Ther. pmid:11207517
Shokri-Shirvani J et al. Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. 2016 Aliment. Pharmacol. Ther. pmid:27137738
Peitz U et al. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study. 2002 Aliment. Pharmacol. Ther. pmid:11860415
Sheu BS et al. Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. 2002 Aliment. Pharmacol. Ther. pmid:12197847
Calvet X et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10792124
Malfertheiner P et al. Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. 2003 Aliment. Pharmacol. Ther. pmid:12752349
Gené E et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. 2003 Aliment. Pharmacol. Ther. pmid:12752350
Vcev A et al. Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. 2000 Aliment. Pharmacol. Ther. pmid:10632647
Gisbert JP et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. 2012 Aliment. Pharmacol. Ther. pmid:22372560
Graham DY et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. 2003 Aliment. Pharmacol. Ther. pmid:12755836